Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: A systematic review and economic evaluation

Health Technology Assessment

Volumn 10, Issue 28, 2006, Pages 1-122

  Shepherd, J ^a   Jones, J ^a   Takeda, A ^a   Davidson, P ^a   Price, A ^a  

^a Southampton Health Technology Assessments Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2A INTERFERON; HEPATITIS B ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VIRUS DNA;

ABDOMINAL PAIN; ADD ON THERAPY; ALOPECIA; ARTHRALGIA; ASTHENIA; BACKACHE; BRONCHITIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; COUGHING; DATA ANALYSIS; DATA BASE; DEATH; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DYSPEPSIA; ECONOMIC EVALUATION; EPIDEMIOLOGICAL DATA; FATIGUE; FEVER; FLATULENCE; FLU LIKE SYNDROME; FOLLOW UP; GINGIVA BLEEDING; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFORMATION RETRIEVAL; INJECTION SITE REACTION; INSOMNIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MONOTHERAPY; MYALGIA; NATIONAL HEALTH SERVICE; NAUSEA; NEPHROTOXICITY; OUTCOME ASSESSMENT; PAIN; PHARYNGITIS; PRURITUS; QUALITY OF LIFE; RANDOMIZATION; RASH; RELAPSE; REMISSION; RETREATMENT; REVIEW; RHINITIS; RIGOR; RISK REDUCTION; SCORING SYSTEM; SENSITIVITY ANALYSIS; SEROCONVERSION; SHORT FORM 36; SORE THROAT; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; UNITED KINGDOM; UPPER RESPIRATORY TRACT INFECTION;

EID: 33749670275     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta10280     Document Type: Review

References (136)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089-94.
2. Chu CM, Karayiannis P, Fowler MJ, Monjardino J, Liaw YF, Thomas HC. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology 1985;5:431-4.
3. De Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, et al. EASL international consensus conference on hepatitis B, 13-14 September, 2002, Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003;39 (Suppl 1):S3-25.
4. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;ii:588-91.
5. Crook PD, Jones ME, Hall AJ. Mortality of hepatitis B surface antigen-positive blood donors in England and Wales. Int J Epidemiol 2003; 32:118-24.
6. Lessells R, Leen C. Management of hepatitis B in patients coinfected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 2004;23:366-74.
7. Thio CL, Seaberg EC, Skolasky JR, Phair J, Visscher B, Oz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-6.
8. Grosheide PM, Wladimiroff JW, Heijtink RA, Mazel JA, Christiaens GC, Nuijten AS, et al. Proposal for routine antenatal screening at 14 weeks for hepatitis B surface antigen. Dutch Study Group on Prevention of Neonatal Hepatitis. BMJ 1995;311:1197-99.
9. Department of Health. Getting ahead of the curve: a strategy for combating infectious diseases (including other aspects of health protection). London: HMSO; 2002.
10. Hahne S, Ramsay M, Balogun K, Edmunds WJ, Mortimer P. Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: implications for immunisation policy. J Clin Virol 2004;29:211-20.
11. Balogun K, Ramsay M, Fairley C, Collins M, Heptonstall J. Acute hepatitis B infection in England and Wales: 1985-96. Epidemiolo Infect 1999;122:125-31.
12. Foundation for Liver Research. Hepatitis B: out of the shadows - a report into the impact of hepatitis B on the nation's health. London: Foundation for Liver Research; 2004.
13. Weild AR, Gill ON, Bennett D, Livingstone SJ, Parry JV, Curran L. Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey [see comment]. Commun Dis Public Health 2000;3:121-6.
14. Gay NJ, Hesketh LM, Osborne KP, Farrington CP, Morgan-Capner P, Miller E. The prevalence of hepatitis B infection in adults in England and Wales. Epidemiol Infect 1999;122:133-8.
15. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis [see comment]. Hepatology 1998; 27:209-12.
16. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664-75.
17. Pojoga C, Dumitrascu DL, Pascu O, Grigorescu M, Radu C, Damian D. Impaired health-related quality of life in Romanian patients with chronic viral hepatitis before antiviral therapy. Eur J Gastroenterol Hepatol 2004;16:27-31.
18. Aggarwal R, Ranjan P. Preventing and treating hepatitis B infection. BMJ 2004;329:1080-6.
19. Department of Health. The National Strategy for Sexual Health and HIV London: HMSO;2001.
20. The British Liver Trust, the British Association for the Study of the Liver, the British Society for Gastroenterology. National plan for liver services UK: specialised services for hepatology and hepato-pancreatobiliary (HPB) Surgery. London; 2004.
21. Department of Health. Hepatitis C strategy for England. London: Department of Health; 2002.
22. British Association of Sexual Health and HIV (BASHH). United Kingdom national guideline on the management of the viral hepatitides A, B and C. London: BASHH; 2005.
23. Brook MG, Gilson R, Wilkins EL, Main J, Gilson R, Hughes N, et al. BHIVA guidelines: coinfection with HIV and chronic hepatitis B virus. HIV Med 2003;4 (Suppl 1):42-51.
24. Gilead Sciences. Adefovir dipivoxil (Hepsera®) for the treatment of chronic hepatitis B. Industry submission to NICE. Cambridge: Gilead Sciences; 2005.
25. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc nat Acad Sci USA 1996;93:4398-402.
26. Ikeda T, Lever AM, Thomas HC. Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life. Hepatology 1986;6:962-5.
27. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha 2a and 2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review. Health Technol Assess 2004;8(39).
28. Cooksley WG. Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin Liver Dis 2004; 24 (Suppl 1):45-53.
29. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Clinical and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int J Technol Assess Health Care 2005;21:47-54.
30. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. CRD Report No 4, 2nd ed. York: York Publishing Services; 2001.
31. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7.
32. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
33. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90.
34. Sung JJY, Lai JY, Zeuzem S, Chow WC, Heathcote E, Perrillo R, et al. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis. J Hepatol 2003; 38 (Suppl 2):25-6.
35. Pecters MG, Hann HH, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101.
36. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-17.
37. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305.
38. Lau G, Piratvisuth T, Luo KX, Marcellin P, Thongasawat S, Cooksley G, et al. Peginterferon alfa-2a (40KD) (PEGASYS (R)) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B: results from a large, multinational study. Hepatology 2004; 40 (4 Suppl 1): 171A.
39. Roche. Pegasys (pegylated interferon alfa-2a): achieving clinical excellence in the treatment of chronic hepatitis B. Submission to NICE. Welwyn Garden City, Hertfordshire: Roche; 2005.
40. Lau GKK, Piratvisuth T, Luo KX, Marcellin P, Thongasawat S, Cooksley G, et al. Pginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95.
41. Hadziyannis S, Tassopolous N, Heathcote EJ, Chang T-T, Kitis G, Rizetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Eng J Med 2005;352:2673-81.
42. Marcellin P, Chang TT, Lim S, Sievert W, Tong M, Arterburn S, et al. Long term efficacy and safety of adefovir dipivoxil (ADV) 10 mg in HBeAg plus chronic hepatitis B (CHB) patients: increasing serologic, virologic and biochemical response over time. Hepatology 2004;40 (4 Suppl 1):655A.
43. Chang TT, Shiffman M, Tong M, Marcellin P, Liaw YF, Luengrojanakul P, et al. Durability of HBeAg seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB). J Hepatol 2004;40:424.
44. Willems B, Lau G, Leung N, Schiff E, Trepo C, Wright T, et al. Safety and efficacy of adding adefovir dipivoxil to lamivudine therapy in compensated chronic hepatitis B patients with YMDD variant HBV and a reduced response to lamivudine: 52 week results. Antivir Ther 2002;7:45.
45. Perrillo R, Willems B, Leung N, Trepo C, Hann H, Lau G, et al. Continued safety and efficacy of adding adefovir dipivoxil (ADV) to ongoing lamivudine (LAM) therapy in compensated chronic hepatitis B (CHB) patients with YMDD variant HBV: 2 year results. J Hepatol 2004;40 (Suppl 1): 130.
46. Westland C, Delaney W, Yang H, Chen SS, Marcellin P, Hadziyannis S, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 2003;125(1):107-16.
47. Hadziyannis S, Tassopoulos N, Chang T, Heathcote J, Kitis G, Rizzetto M, et al. Three year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) in HBeAg-negative chronic hepatitis B (CHB). Oral presentation at the 39th Annual Meeting of the European Association for the Study of the Liver, Berlin, Germany, 14-18 April 2004 and at Digestive Disease Week, New Orleans, USA, 15-20 May 2004.
48. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-96.
49. Lok ASF, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22.
50. Dando T, Plosker G. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 2003;63:2215-34.
51. Benbamou Y, Thibault V, Vig P, Valantin MA, Guyon P, Katlama C, et al. Long term treatment with adefovir dipivoxil (ADV) for three years in patients with lamivudine-resistant (LAM-R) HBV and HIV co-infection results in significant and sustained clinical improvement. Hepatology 2003;38 (4 Suppl 1):714A.
52. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Sullivan M, et al. 96 week efficacy and safety of adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in chronic hepatitis B patients co-infected with HIV. Hepatology 2002;36 (4 Part 2):638A.
53. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Sullivan M, et al. Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients. J Hepatol 2002;36 (Suppl 1):138.
54. Benhamou Y, Thibault V, Vig P, Valantin MA, Guyon P, Katlama C, et al. Significant and sustained efficacy of adefovir dipivoxil (ADV) after four years of treatment in chronic hepatitis B (CHB) patients with lamivudine-resistant (LAM-R) HBV and HIV co-infection. Gastroenterology 2004; 126:A660.
55. Benhamou Y, Bochet M, Thibault V, Brosgart C, Vig P, Gibb C, et al. Safety and efficacy of adefovir dipivoxil for lamivudine resistant HBV in HIV infected patients. J Hepatol 2001;34 (Suppl 1):24.
56. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, et al. An open label pilot study of the safety and efficacy of adefovir dipivoxil in HIV/HBV co-infected patients with lamivudine resistant HBV Antiviral Res 2001;51:47.
57. Benhamou Y, Bochet M, Thibault V, Vig P, Brosgart CL, Fry J, et al. Safety and efficacy of adefovir dipivoxil for lamivudine resistant HBV in HIV infected patients. Hepatology 2001;34 (4 Part 2):319A.
58. Benhamou Y, Bagnis CI, Hannon H, Beaufils H, Sullivan M, Brosgart C, et al. Renal tolerance of adefovir dipivoxil 10 mg in lamivudine resistant hepatitis B/HIV co-infected individuals. Hepatology 2002;36:1841.
59. Brosgart CL, Hadziyannis S, Benhamou Y, Arterburn S, Ma J, Lu B, et al. Long-term adefovir dipivoxil (ADV) demonstrates sustained efficacy in chronic hepatitis B (CHB). Antiviral Res 2004;62:51.
60. Gilson RJC, Chopra K, Murray L, I, Newell A, Nelson M, Tedder RS, et al. A placebo-controlled phase I/II study of adefovir dipivoxil (bis-POM PMEA) in patients with chronic hepatitis B infection [AASLD abstract]. Hepatology 1996;24 (4 Part 2):281A.
61. Marcellin P, Hadzyannis S, Schiff E, Peters M, Benhamou Y, Brosgart C, et al. Adefovir dipivoxil 10 mg (ADV) results in consistent efficacy in chronic hepatitis B (CHB) patients with diverse baseline characteristics. J Hepatol 2003;38:529.
62. Marcellin P, Hadziyannis S, Schiff E, Peters M, Benhamou Y, Brosgart C, et al. Adefovir dipivoxil 10 mg results in consistent efficacy in chronic hepatitis B patients with diverse baseline characteristics. J Hepatol 2003;38:153-4.
63. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients [see comment]. Hepatology 2003;38:I419-27.
64. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Lampertico P, et al. Adefovir dipivoxil 10 mg (ADV) for the treatment of chronic hepatitis B in patients pre-liver transplantation with lamivudine-resistant patients. Hepatology 2003;38 (4 Suppl 1): 161A.
65. Schiff E, Lai CL, Neuhaus P, Virchow CC, Tillmann H, Samuel D, et al. Long-term safety and efficacy of adefovir dipivoxil (ADV) in the treatment of chronic hepatitis B in patients pre-and post- liver transplantation (OLT) with lamivudine-resistant (LAM-R) hepatitis B virus (HBV). Hepatology 2004;40 (4 Suppl 1):660A.
66. Westland CE, Villeneuve JP, Terrault NA, Zoulin F, Brosgart CL, Wulfsohn M, et al. Resistance surveillance of liver transplantation patients with lamivudine-resistant hepatitis B virus (HBV) after 96 weeks of adefovir dipivoxil treatment. Hepatology 2003;38 (4 Suppl 1):160A.
67. Barcena R, Casanovas T, Prieto M, Buti M, Moreno JM, Cuervas V, et al. Preliminary data for the treatment of adefovir in transplant patients with hepatitis B (HBV) resistant to lamivudine. J Hepatol 2004;40:102.
68. Beckebaum S, Malago M, Dirsch O, Cicinnati VR, Trippler M, Lampertico P, et al. Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation. Clin Transplant 2003;17:554-9.
69. Chan HLY, Chui AKK, Lau WY, Chan FKL, Hui AY, Rao N, et al. Impact of lamivudine resistant mutants in hepatitis B virus related liver diseases after liver transplantation. Hepatology 2003;38 (4 Suppl 1):536A-537A.
70. Toniutto P, Fumo E, Caldato M, Apollonio L, Perin A, Pirisi M. Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation. Transplantation 2004;77:472-3.
71. Wang ZX, Ding GS, Fu H, Zhang JJ, Chen XS, Guo WY, et al. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. Hepatobil Pancreat Dis Int 2004;3:345-8.
72. Ahmad J, Dodson SF, Balan V, Vargas HE, Fung JJ, Rakela J, et al. Adefovir dipivoxil suppresses lamivudine resistant hepatitis B virus in liver transplant recipients. Hepatology 2000;32:522.
73. Foxton M, Maulayah P, Lama N, Norris S. Efficacy and safety of adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B pre- and post liver transplantation. Hepatology 2002;36:1980.
74. Papatheodoyidis GV, Sevastianos V, Burroughs AK. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant 2003;3:250-8.
75. Bui HSH, Martin P. Liver transplantation for hepatitis B. Hepatol Res 2004;29:193-201.
76. Yu AS, Keeffe EB. Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period. Clin Liver Dis 2003;7:551-72.
77. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000;6:429-33.
78. Lim SG, Marcellin P, Tassopoulos N, Hadziyannis S, Chang TT, Tong M, et al. Lack of ethnic differences in response to adefovir dipivoxil therapy in HBeAg+ and HBeAg- patients with chronic hepatitis B. Hepatology 2003;38:1159.
79. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005;142:821-31.
80. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995;22:1863-73.
81. Crowley SJ, Tognarini D, Desmond PV, Lees M. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000;17:409-27.
82. Brooks EA, Lacey LF, Payne SL, Miller DW. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States. Am J Manage Care 2001;7:677-82.
83. Orlewska E. The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland. Value Health 2002;5:404-20.
84. Crowley S, Tognarini D, Desmond P, Lees M, Saal G. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 2002;17:153-64.
85. Franco J, Saeian K. Role of antiviral therapy in the prevention of hepatocellular carcinoma. J Vasc Interven Radiol 2002;13:S191-6.
86. Wands JR, Blum HE. Primary hepatocellular carcinoma. N Engl J Med 1991;325:729-31.
87. Aggarwal R, Ranjan P. Preventing and treating hepatitis B infection. BMJ 2004;329:1080-6.
88. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004;2:87-106.
89. Fattovich G. Natural history of hepatitis B. J Hepatol 2003;39 (Suppl 1):50-8.
90. Di Marco V, Lo IO, Camma C, Vaccaro A, Giunta M, Martorana G, et al. The long-term course of chronic hepatitis B. Hepatology 1999;30:257-64.
91. Schalm S, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-8.
92. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.
93. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
94. van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420-4.
95. Goodman Z, Dhillon AP, Wu PC, Gray F, Atkins M, Stevenson C, et al. Lamivudine treatment reduces progression to cirrhosis in patients with chronic hepatitis B. J Hepatol 1999;30 (Suppl 1):59.
96. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114:629-34.
97. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991;32:294-8.
98. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522-27.
99. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38:1267-73.
100. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-55.
101. Owens DK, Cardinalli AB, Nease RF Jr. Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. Qual Life Res 1997;6:77-86.
102. Wright M, Forton D, Main J, Goldin R, Torok E, Tedder R, et al. Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. J Viral Hepat 2005;12:58-66.
103. Dolan P, Gudex C, Kind P, Williams A. A social tariff for Euroqol: results from a general population survey. Centre for Health Economics Discussion Paper 138. York: Centre for Health Economics, University of York; 1995.
104. Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programs. Health Serv Res 1972;7:118-33.
105. Owens DK. In the eye of the beholder: assessment of health-related quality of life. Hepatology 1981;27:292-3.
106. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993;306:1437-40.
107. Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 2001;96:2199-205.
108. Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001;96:579-83.
109. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-65.
110. Lok ASF. Response to "Is it meaningful to pursue the safety of long-term lamivudine treatment in patients with chronic hepatitis B." Lo, GH, Lai KH. Gastroenterology 2004;126:1932-3.
111. Kind P, Hardman G, Macran SUK. Population norms for EQ-5D. CHE Discussion Paper 172. York; Centre for Health Economics, University of York, 1999.
112. Lok ASF, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004;39:857-61.
113. Longworth L, Ratcliffe J, Young T, Bryan S. A comparison of the EQ-5D and SF-6D single index in assessing the health-related quality of life of liver transplant patients. In Proceedings of the 18th Plenary Meeting of the EuroQol Group, Copenhagen, Denmark. Lund: The Swedish Institute for Health Economics, 2002.
114. Longworth L, Young T, Ratcliffe J, Bryan S, Buxton M. Economic evaluation of the Transplantation Programme in England and Wales: an assessment of the costs of liver transplantation. Uxbridge: Brunel University. Report to the Department of Health, 2001.
115. Hadziyannis S, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617-24.
116. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988;8:493-6.
117. Wong D, Cheung A, O'Rourke K, Naylor C, Detsky A, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23.
118. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH conference. Hepatocellular carcinoma. Ann Intern Med 1988;108:390-401.
119. Lau DT, Everhart J, Kleiner DL. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-7.
120. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha 2a and 2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review. Health Technol Assess 2004;8(39).
121. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.
122. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002;74:427-37.
123. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997;27:201-5.
124. Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis e antigen seroconversion rates: Results after three years of therapy. Hepatology 2001;33:1527-32.
125. Liaw YF, Leung NWY, Chang TT, Guan R, Tai D-I, Ng K-Y, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-80.
126. Papatheodoridis GV, Hadziyannis SJ. Review article: current management of chronic hepatitis B. Aliment Pharmacol Ther 2004;19:25-37.
127. Santantonio T, Niro GA, Sinisi E, Leandro G, Insalata M, Guastadisegni A, et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002;36:799-804.
128. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-6.
129. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Gray DF, et al. Post lamivudine treatment follow up of patients with HBeAg negative chronic hepatitis B. J Hepatol 1991;30 (Suppl 1): 117.
130. Ratcliffe J, Longworth L, Young T, Bryan S, Burroughs A, Buxton M, et al. Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl 2002;8:263-70.
131. Hopwood M, Southgate E. Living with hepatitis C: a sociological review. Crit Public Health 2003;13:251-67.
132. van Nunen AB, Janssen HL, Wolters LM, Niesters HG, de Man RA, Schalm SW. Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug? Antiviral Res 2001;52:139-46.
133. Janssen HL, van Zonneveld M, Senturk H, Zeuzeni S, Akarca U, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365: 123-9.
134. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. [summary for patients in Ann Intern Med. 2005; 142(4):I30; PMID: 15710953]. Ann Intern Med 2005;142(4):240-50.
135. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003;348:177-8.
136. Van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-5.